Cisiv Ltd, an award-winning technology company in the real-world late phase space, has today announced a joint investment from Abbey International Finance and Ryan Group Holdings.

The investment will accelerate the expansion of Civis’ platform, Baseline Plus, and support the company’s journey to deliver the best technology for Real World Data (RWD) collection.

The platform, developed for post-approval, provides efficient solutions to the various challenges of gathering prospective observational and primary data in a real-world setting and has become the solution of choice for many large pharmaceutical manufacturers and CROs.

Baseline Plus is used in a wide range of non-interventional and low interventional activities including orphan drug studies and rare disease registries, health economics and outcomes studies (HEOR), large scale mandated post approval safety studies, managed access programmes, and many other study types and data-related activities across a broad range of therapeutic areas.

Dominic Farmer, CEO and co-founder of Cisiv, commented:

“We have seen a transformation of the market and a recognition that technology solutions can help deliver evidence more efficiently. We are thrilled to see the uptake of Baseline Plus to enable market access, real-world evidence for health outcomes and patient reported outcomes. This new funding will help us to scale our operations and commercial teams to help deliver real-world data to more life science partners.”

Over the last few years, Cisiv has delivered real-world data in more than 300 studies, in over 60 countries, and serving over 40 of the top pharma and biotech organisations.

For more information, visit: https://cisiv.com/

-Ends-